1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 1 , 1 , 34 ,
      ESC Heart Failure
      John Wiley and Sons Inc.
      Acute heart failure, Diuretics, Urinary sodium, Decongestion, Protocol

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step‐wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively.

          Methods and results

          The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT‐HF) study is an international, multicentre, non‐randomized, open‐label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous loop diuretic therapy, aiming to enrol 500 patients. Inclusion criteria are as follows: at least one sign of volume overload (oedema, ascites, or pleural effusion), use ≥ 40 mg of furosemide or equivalent for >1 month, and a BNP > 250 ng/L or an N‐terminal pro‐B‐type natriuretic peptide > 1000 pg/L. The study is designed in two sequential phases. During Phase 1, all centres will treat consecutive patients according to the local standard of care. In the Phase 2 of the study, all centres will implement a standardized diuretic protocol in the next cohort of consecutive patients. The protocol is based upon the recently published HFA algorithm on diuretic use and starts with intravenous administration of two times the oral home dose. It includes early assessment of diuretic response with a spot urinary sodium measurement after 2 h and urine output after 6 h. Diuretics will be tailored further based upon these measurements. The study is powered for its primary endpoint of natriuresis after 1 day and will be able to detect a 15% difference with 80% power. Secondary endpoints are natriuresis and diuresis after 2 days, change in congestion score, change in weight, in‐hospital mortality, and length of hospitalization.

          Conclusions

          The ENACT‐HF study will investigate whether a step‐wise diuretic approach, based upon early assessment of urinary sodium and urine output as proposed by the HFA, is feasible and able to improve decongestion in AHF with volume overload.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Diuretic strategies in patients with acute decompensated heart failure.

            Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2.5 times the previous oral dose). The protocol allowed specified dose adjustments after 48 hours. The coprimary end points were patients' global assessment of symptoms, quantified as the area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and the change in the serum creatinine level from baseline to 72 hours. In the comparison of bolus with continuous infusion, there was no significant difference in patients' global assessment of symptoms (mean AUC, 4236±1440 and 4373±1404, respectively; P=0.47) or in the mean change in the creatinine level (0.05±0.3 mg per deciliter [4.4±26.5 μmol per liter] and 0.07±0.3 mg per deciliter [6.2±26.5 μmol per liter], respectively; P=0.45). In the comparison of the high-dose strategy with the low-dose strategy, there was a nonsignificant trend toward greater improvement in patients' global assessment of symptoms in the high-dose group (mean AUC, 4430±1401 vs. 4171±1436; P=0.06). There was no significant difference between these groups in the mean change in the creatinine level (0.08±0.3 mg per deciliter [7.1±26.5 μmol per liter] with the high-dose strategy and 0.04±0.3 mg per deciliter [3.5±26.5 μmol per liter] with the low-dose strategy, P=0.21). The high-dose strategy was associated with greater diuresis and more favorable outcomes in some secondary measures but also with transient worsening of renal function. Among patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose as compared with a low dose. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00577135.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology

              The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving a state of euvolaemia, mainly through the use of diuretic therapy. The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. This position paper focuses on the use of diuretics in heart failure with congestion. The manuscript addresses frequently encountered challenges, such as (i) evaluation of congestion and clinical euvolaemia, (ii) assessment of diuretic response/resistance in the treatment of acute heart failure, (iii) an approach towards stepped pharmacologic diuretic strategies, based upon diuretic response, and (iv) management of common electrolyte disturbances. Recommendations are made in line with available guidelines, evidence and expert opinion.
                Bookmark

                Author and article information

                Contributors
                wilfried.mullens@zol.be
                Journal
                ESC Heart Fail
                ESC Heart Fail
                10.1002/(ISSN)2055-5822
                EHF2
                ESC Heart Failure
                John Wiley and Sons Inc. (Hoboken )
                2055-5822
                28 October 2021
                December 2021
                : 8
                : 6 ( doiID: 10.1002/ehf2.v8.6 )
                : 4685-4692
                Affiliations
                [ 1 ] Department of Cardiology Ziekenhuis Oost‐Limburg Schiepse Bos 6 Genk 3600 Belgium
                [ 2 ] UHasselt‐Hasselt University, Doctoral School for Medicine and Life Sciences LCRC Diepenbeek Belgium
                [ 3 ] Department of Noninvasive Cardiology Medical University of Lodz Lodz Poland
                [ 4 ] Department of Cardiology, Heart Failure and Heart Transplant Unit Hospital de la Santa Creu i Sant Pau Barcelona Spain
                [ 5 ] Instituto Nacional de Cardiología Ignacio Chávez Ciudad de México Mexico
                [ 6 ] Theracardia Clinic Brasov Romania
                [ 7 ] Pushpagiri Institute of Medical Sciences Tiruvalla India
                [ 8 ] Department of Cardiology Hospital Universitario Puerta de Hierro Madrid Spain
                [ 9 ] Centro de Investigación Biomédica en Red Madrid Spain
                [ 10 ] Department of Cardiology University Heart and Vascular Center Hamburg Hamburg Germany
                [ 11 ] Department of cardiology, sonography and functional diagnostics First Moscow State Medical University Moscow Russia
                [ 12 ] Wetchakarunrasm Hospital Bangkok Thailand
                [ 13 ] Zan Mitrev Clinic Skopje Macedonia
                [ 14 ] Division of Cardiology Città della Salute e della Scienza University Hospital of Torino Torino Italy
                [ 15 ] Emergency Department, IDIBAPS University of Barcelona Barcelona Spain
                [ 16 ] University Hospitals of North Midlands Stoke on Trent UK
                [ 17 ] Department of Cardiology, Faculty of Medicine University of Debrecen Debrecen Hungary
                [ 18 ] Department of Cardiology Mount Lebanon Hospital‐Balamand University Medical Center Hazmiyeh Lebanon
                [ 19 ] Department of Cardiology, CHU Ibn Sina Mohammed V University Rabat Morocco
                [ 20 ] Cardiology Department Hospital Clínico Universitario de Valencia Valencia Spain
                [ 21 ] The Heart Centre Royal Infirmary of Edinburgh Edinburgh UK
                [ 22 ] Department of Cardiology Michele e Pietro Ferrero Hospital Verduno Italy
                [ 23 ] Department of Cardiology Hospital Professor Doutor Fernando Fonseca Amadora Portugal
                [ 24 ] Kuala Lumpur General Hospital Kuala Lumpur Malaysia
                [ 25 ] Department of Cardiology Thorax Centrum Twente, Medisch Spectrum Twente Enschede The Netherlands
                [ 26 ] Benyoucef Benkhedda Faculty of Medicine, Mustapha Pacha Hospital University of Algiers Algiers Algeria
                [ 27 ] Department of Internal Medicine Red Cross Hospital Bremen Germany
                [ 28 ] Jordan Hospital Amman Jordan
                [ 29 ] Department of Cardiology Abdali Hospital Amman Jordan
                [ 30 ] Complexo Hospitalario Universitario de A Coruña (CHUAC), Servicio Galego de Saúde (SERGAS) Instituto de Investigación Biomédica de A Coruña (INIBIC) A Coruña Spain
                [ 31 ] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) Instituto de Salud Carlos III Madrid Spain
                [ 32 ] National Heart Institute Kuala Lumpur Malaysia
                [ 33 ] I‐BioStat, Data Science Institute Hasselt University Diepenbeek Belgium
                [ 34 ] Faculty of Medicine and Life Sciences, LCRC UHasselt, Biomedical Research Institute Diepenbeek Belgium
                Author notes
                [*] [* ]Correspondence to: Wilfried Mullens, Department of Cardiology, Ziekenhuis Oost‐Limburg, Schiepse Bos 6, 3600 Genk, Belgium. Tel: +32 89 327100; Fax: +32 89 327918. Email: wilfried.mullens@ 123456zol.be
                Author information
                https://orcid.org/0000-0003-4605-3450
                https://orcid.org/0000-0003-0756-5541
                https://orcid.org/0000-0001-9742-8537
                https://orcid.org/0000-0003-0734-6437
                https://orcid.org/0000-0002-8209-2791
                https://orcid.org/0000-0002-2977-3299
                https://orcid.org/0000-0002-7924-9751
                https://orcid.org/0000-0002-3695-6042
                https://orcid.org/0000-0002-8720-3999
                https://orcid.org/0000-0002-7358-9712
                https://orcid.org/0000-0002-0331-3358
                https://orcid.org/0000-0001-5561-5940
                https://orcid.org/0000-0001-5662-5323
                https://orcid.org/0000-0002-6978-3002
                https://orcid.org/0000-0002-6036-2113
                https://orcid.org/0000-0001-9995-8590
                Article
                EHF213666 ESCHF-21-00660
                10.1002/ehf2.13666
                8712839
                34708555
                95733b15-bc6a-4afe-838e-889ade46565e
                © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 20 September 2021
                : 06 July 2021
                : 27 September 2021
                Page count
                Figures: 3, Tables: 2, Pages: 8, Words: 3285
                Funding
                Funded by: Limburg Sterk Merk (LSM) , doi 10.13039/501100009542;
                Categories
                Study Design
                Study Designs
                Custom metadata
                2.0
                December 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.0 mode:remove_FC converted:28.12.2021

                acute heart failure,diuretics,urinary sodium,decongestion,protocol

                Comments

                Comment on this article